Source comparison
Stop Taking PT-141: Discontinuation Scenarios Comparison
Abrupt cessation after 6+ months twice-weekly use 4–6 weeks Moderate to severe; 40–60% below baseline for 10–14 days Patients who need to stop immediately due to side effects or contraindications Expect pronounced rebound. Receptor downregulation is maximal. M
This comparison does not assign a generated winner or score.
- Abrupt cessation after 6+ months twice-weekly use
- 4–6 weeks
- Moderate to severe; 40–60% below baseline for 10–14 days
- Patients who need to stop immediately due to side effects or contraindications
- Expect pronounced rebound. Receptor downregulation is maximal. Mitigate with dopaminergic support (exercise, sleep optimisation) during nadir phase.
- Tapered cessation over 3 weeks (interval extension)
- 3–4 weeks
- Mild; 15–25% below baseline for 7–10 days
- Patients with 8+ weeks prior use who can plan discontinuation in advance
- Gold standard approach. Allows receptor upregulation to begin during taper, smoothing the transition. Minimal rebound reported.
- Abrupt cessation after 6–8 weeks sporadic use
- 2–3 weeks
- Minimal to none; return to baseline within 5–7 days
- Patients who used PT-141 infrequently or for short duration
- Receptor downregulation is minimal. Abrupt stop is well-tolerated. Taper not required.
- Restart during washout window (days 5–14)
- Recovery stalls; tachyphylaxis accelerates on restart
- N/A. Rebound avoided but receptor sensitivity compromised
- Not recommended; interrupts upregulation
- Restarting before receptor recovery completes blunts long-term response. Wait 4+ weeks for full washout.
- Cold turkey after high-frequency use (3x weekly or more)
- 5–7 weeks
- Severe; 50–70% below baseline for 14–21 days
- Emergency discontinuation only
- High-frequency use drives maximal receptor downregulation. Expect extended nadir. Taper strongly preferred if time permits.
- The comparison table demonstrates that discontinuation strategy has measurable impact on rebound severity and recovery duration. Patients with the longest prior use benefit most from structured tapers, while those with short or sporadic use tolerate abrupt cessation without significant rebound.